Drug Price Competition and Patent Term Restoration Act of 1984Word格式.docx
- 文档编号:13196900
- 上传时间:2022-10-08
- 格式:DOCX
- 页数:15
- 大小:20.38KB
Drug Price Competition and Patent Term Restoration Act of 1984Word格式.docx
《Drug Price Competition and Patent Term Restoration Act of 1984Word格式.docx》由会员分享,可在线阅读,更多相关《Drug Price Competition and Patent Term Restoration Act of 1984Word格式.docx(15页珍藏版)》请在冰豆网上搜索。
ChiefCounsel
U.S.FoodandDrugAdministration
before
theSenateCommitteeontheJudiciary
AUGUST1,2003
INTRODUCTION
Mr.ChairmanandMembersoftheSubcommittee,IamDanielE.Troy,ChiefCounselfortheUnitedStatesFoodandDrugAdministration(FDAortheAgency).IamjoinedbyGaryBuehler,R.Ph.,Director,OfficeofGenericDrugs,CenterforDrugEvaluationandResearch.
IampleasedtobewithyoutodaytodiscussFDA'
simplementationoftheDrugPriceCompetitionandPatentTermRestorationActof1984,commonlyknownastheHatch-WaxmanAmendmentsandrecentCongressionalactiononamendmentstoHatch-Waxman.
ThistestimonywilldiscussanumberofissuesthataffectthetimelyintroductionofgenericdrugsintotheU.S.marketplace.Itwillfocusinparticularonwhethercertain"
later-listed"
patentsorinappropriatepatentsubmissionsbythesponsorsofinnovatordrugproductshaveresultedinthedelayofgenericdrugapprovals.OnJune18,2003,FDApublisheditsfinalruleintendedtospeedaccesstoandincreasetheavailabilityofgenericdrugsbylimitingtheuseof30-monthstaysbybrand-namedrugsponsorsandbyclarifyingthetypesofpatentsthatmustandmustnotbesubmittedtoFDAforlistingintheOrangeBook.
TheHatch-WaxmanAmendmentswereintendedtobalancetwoimportantpublicpolicygoals.First,Congresswantedtoensurethatbrand-name(alsoknownasinnovator)drugmanufacturerswouldhavemeaningfulpatentprotectionandaperiodofmarketingexclusivitytoenablethemtorecouptheirinvestmentsinthedevelopmentofvaluablenewdrugs.Second,Congresssoughttoensurethat,oncethestatutorypatentprotectionandmarketingexclusivityforthesenewdrugshasexpired,consumerswouldbenefitfromtherapidavailabilityoflowerpricedgenericversionsofinnovatordrugs.
Sinceitsenactmentin1984,Hatch-Waxmanhasgovernedthegenericdrugapprovalprocess.Ingeneral,thelawhasbeenworkingwell.Since1984,over10,000genericdrugshaveenteredthemarket,andgenericsnowaccountforcloseto50percentofprescriptionsfilled.Attentionhasrecentlyfocusedontwokeyprovisionsofthelawthatallowfor180daysofmarketingexclusivitytocertaingenericdrugapplicants,andforthe30-monthstayongenericapprovals.Bothoftheseprovisionsarediscussedindetailbelow.
FDA'
sobjectiveistoenhancetheabilityofinnovators,genericfirmsandtheAgencytoachievethegoalsembodiedinHatch-Waxman.WhilethenewrulewillimproveFDA'
simplementationofthelaw,thisisonlyonepartofasetofFDAinitiativesthatwillreducedrugcostsbyencouraginginnovationandspeedingupthedrugdevelopmentandapprovalprocess,whilemaintainingFDA'
shighstandardsforsafetyandeffectiveness.Ourreformsinthegenericapprovalprocesswillgenerallyshavemonthsoffthetimetoavailabilityofgenericdrugsacrosstheboard.Similarly,newpathwaysforapprovinginhaledandtopicalgenericdrugswillpotentiallyaffectmanyproducts.Thisbroadimprovementintheavailability,ofbothnewdrugsandgenericdrugs,willhaveapositiveimpactonallpatients,notjustthoseaffectedbyimperfectionsintheoperationofHatch-Waxman.
STATUTORYPROVISIONS
TheHatch-WaxmanAmendmentsamendedtheFederalFood,Drug,andCosmeticAct(FD&
CAct)andcreatedastatutorygenericdrugapprovalprocesswithsection505(j).Section505(j)establishedtheabbreviatednewdrugapplication(ANDA)approvalprocess,whichpermitsgenericversionsofpreviouslyapprovedinnovatordrugstobeapprovedwithoutsubmittingafullnewdrugapplication(NDA).AnANDAreferstothepreviouslyapprovedNDA(the"
listeddrug"
)andreliesontheAgency,sfindingofsafetyandeffectivenessforthelisteddrugproduct.
ThetimingofanANDAapprovaldependsinpartonpatentprotectionsfortheinnovatordrug.Innovatordrugapplicantsmustinclude,inanNDA,informationaboutpatentsrelatingtothedrugproductthatisthesubjectoftheNDA.FDAisrequiredtopublishthepatentinformationsubmittedoncethedrugisapproved.ThestatuteestablishesaprocessthatrequiresthatANDAapplicantscertifytothepatentslisted,providenoticetotheNDAholderandpatentowner,and,ifpatentinfringementlitigationisfiled,itimposesa30~monthstayontheapprovalofanANDA.TheHatch-WaxmanAmendmentsalsocreatedaperiodofmarketexclusivityforcertaingenericapplicants.
“ORANGEBOOK”LISTINGS
OnlycertaintypesofpatentinformationcanbesubmittedtoFDA.FDApublishespatentinformationonapproveddrugproductsintheAgency'
spublicationApprovedDrugProductswithTherapeuticEquivalenceEvaluations,alsoknownasthe"
OrangeBook."
TheOrangeBookisavailableonFDA'
swebsiteandisupdatedeveryfewweeks.
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- Drug Price Competition and Patent Term Restoration Act of 1984
链接地址:https://www.bdocx.com/doc/13196900.html